Former Insys CEO pleads guilty to opioid kickback scheme

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. REGN
2. CRWD
3. LITE
4. AAPL
5. ABBV
6. MRVL
7. CL
8. TFII
9. ORCL
10. LYB

Go back to Former Insys CEO pleads guilty to opioid kickback scheme

Insys Therapeutics (INSY) Reports Results of Dose-Finding PK Study for Epinephrine Nasal Spray for Treatment of Anaphylaxis

January 9, 2019 6:08 AM EST

INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the results of a dose-finding pharmacokinetic (PK) study (INS015-18-124) of its epinephrine nasal spray. These results identified a dose that showed a PK profile similar to that of intramuscular injection of EpiPen® (0.3 mg) and Adrenalin® (0.5 mg), both of which are treatments for anaphylaxis, an acute, life-threatening allergic... More